Director at LeonaBio (LONA) granted 56,000 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

LeonaBio, Inc. director Peter B. Silverman received a grant of stock options covering 56,000 shares of common stock. The options have an exercise price of $9.63 per share and expire on May 4, 2036. They vest monthly over 36 months, contingent on his continued service to the company.

Following this grant, Silverman holds 56,000 stock options directly, reflecting a compensation award rather than an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Silverman Peter B.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	56,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 56,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 56,000 options Exercise price: $9.63 per share Expiration date: May 4, 2036 +2 more

5 metrics

Options granted 56,000 options Stock Option (Right to Buy) grant to director on May 5, 2026

Exercise price $9.63 per share Strike price for 56,000 options on LeonaBio common stock

Expiration date May 4, 2036 Option term for the 56,000-share grant

Vesting period 36 months Monthly vesting on anniversaries of grant date, subject to continued service

Post-grant holdings 56,000 options Total stock options held directly by Peter B. Silverman after grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, 2026 Equity Incentive Plan, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "9.6300" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the option are scheduled to vest monthly over a term of 36 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

2026 Equity Incentive Plan financial

"as defined in the Issuer's 2026 Equity Incentive Plan"

Service Provider financial

"subject to the optionee continuing to be a Service Provider"

Form 4 Insider Transactions: What Each Field Means →

05/07/2026 - 08:26 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silverman Peter B.

(Last)

(First)

(Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL

WASHINGTON

98011

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$9.63	05/05/2026		A		56,000		⁽¹⁾	05/04/2036	Common Stock	56,000	$0	56,000	D

Explanation of Responses:

1. The shares subject to the option are scheduled to vest monthly over a term of 36 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

	/s/ Mark Worthington, Attorney in fact for Peter B. Silverman	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did LeonaBio (LONA) report for Peter B. Silverman?

LeonaBio reported that director Peter B. Silverman received a grant of stock options for 56,000 shares of common stock. This is a compensation-related award, not an open-market trade, and gives him the right to buy shares at a set price in the future.

How many LeonaBio (LONA) stock options were granted and at what exercise price?

Peter B. Silverman was granted stock options for 56,000 shares of LeonaBio common stock. The options carry an exercise price of $9.63 per share, meaning he can purchase shares at that fixed price once the options have vested, subject to plan terms.

What is the vesting schedule of the new LeonaBio (LONA) stock options?

The 56,000 LeonaBio stock options granted to Peter B. Silverman vest monthly over 36 months. Vesting occurs on monthly anniversaries of the grant date, provided he continues as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan through each vesting date.

When do Peter B. Silverman’s LeonaBio (LONA) stock options expire?

The stock options granted to Peter B. Silverman are scheduled to expire on May 4, 2036. After that expiration date, any unexercised options will lapse, and he will no longer have the right to buy LeonaBio common shares under this specific grant.

Did Peter B. Silverman buy or sell LeonaBio (LONA) shares on the market?

No, this filing shows a grant of stock options as compensation, not a market trade. Silverman received options to acquire 56,000 shares at $9.63, which may be exercised in the future after vesting, rather than buying or selling existing shares today.

How many LeonaBio (LONA) stock options does Peter B. Silverman hold after this grant?

After this grant, Peter B. Silverman holds 56,000 stock options directly. These options represent his right to purchase up to 56,000 LeonaBio common shares at $9.63 per share, subject to the vesting schedule and the expiration date of May 4, 2036.